# Development Roadmap: 0 to Launch
## Closed-Loop Diabetes Management System

**Document Version:** 1.0
**Date:** 2025-11-23
**Status:** Draft

---

## Table of Contents
1. [Overview](#1-overview)
2. [Phase 0: Foundation (Months 1-6)](#2-phase-0-foundation-months-1-6)
3. [Phase 1: MVP Development (Months 7-12)](#3-phase-1-mvp-development-months-7-12)
4. [Phase 2: Clinical Validation (Months 13-30)](#4-phase-2-clinical-validation-months-13-30)
5. [Phase 3: Regulatory Approval (Months 31-48)](#5-phase-3-regulatory-approval-months-31-48)
6. [Phase 4: Launch Preparation (Months 49-52)](#6-phase-4-launch-preparation-months-49-52)
7. [Post-Launch: Continuous Improvement](#7-post-launch-continuous-improvement)

---

## 1. Overview

### 1.1 Timeline Summary

**Total Time to Launch: 48-52 months (4+ years)**

```
Months 1-6:    Foundation & Planning
Months 7-12:   MVP Development
Months 13-18:  Feasibility Study
Months 19-30:  Pivotal Clinical Trial
Months 31-48:  Regulatory Review & Approval
Months 49-52:  Launch Preparation
Month 52+:     Commercial Launch
```

### 1.2 Key Milestones

| Milestone | Target Month | Critical Path |
|-----------|--------------|---------------|
| Team fully hired | Month 3 | ✓ |
| FDA Q-Sub meeting | Month 6 | ✓ |
| MVP complete | Month 12 | ✓ |
| ISO 13485 certification | Month 15 | ✓ |
| Feasibility study complete | Month 18 | ✓ |
| Pivotal trial enrollment complete | Month 24 | ✓ |
| Pivotal trial data complete | Month 30 | ✓ |
| PMA submission | Month 36 | ✓ |
| FDA approval | Month 48 | ✓ |
| Commercial launch | Month 52 | ✓ |

### 1.3 Team Structure

**Initial Team (Month 1):**
- CEO / Co-Founder
- CTO / Co-Founder
- VP Regulatory Affairs
- VP Clinical Affairs

**Full Team (Month 6):**
- **Executive:** CEO, CTO, COO, CMO (Chief Medical Officer)
- **Engineering:** 8-10 engineers (backend, mobile, ML, DevOps)
- **Regulatory & Quality:** 3-4 specialists
- **Clinical:** 2-3 clinical research associates
- **Data Science:** 2-3 ML engineers
- **Product:** Product manager, UX designer
- **Operations:** Finance, HR, Legal

**Total Headcount by Phase:**
- Month 6: ~20 people
- Month 12: ~30 people
- Month 24: ~40 people
- Month 48: ~50 people

---

## 2. Phase 0: Foundation (Months 1-6)

### 2.1 Objectives
- Establish company infrastructure
- Build initial team
- Secure funding
- Initiate regulatory strategy
- Partner with device manufacturers

### 2.2 Month-by-Month Breakdown

#### Month 1: Company Formation
**Goals:**
- [ ] Incorporate company
- [ ] Set up bank accounts
- [ ] File patents (algorithm IP)
- [ ] Hire CEO, CTO
- [ ] Secure seed funding ($2-5M)

**Deliverables:**
- Business plan
- Pitch deck
- IP filing

#### Month 2: Team Building
**Goals:**
- [ ] Hire VP Regulatory Affairs
- [ ] Hire VP Clinical Affairs
- [ ] Engage regulatory consultants
- [ ] Engage law firm (FDA specialty)
- [ ] Office space / remote setup

**Deliverables:**
- Job descriptions
- Hiring pipeline
- Consultant agreements

#### Month 3: Strategic Partnerships
**Goals:**
- [ ] Negotiate with Dexcom (CGM integration)
- [ ] Negotiate with Omnipod (pump integration)
- [ ] Establish clinical advisory board
- [ ] Select CRO (Clinical Research Organization)

**Deliverables:**
- Partnership agreements (NDAs, API access)
- Advisory board formed
- CRO contract

#### Month 4: Regulatory Planning
**Goals:**
- [ ] Draft Pre-Submission (Q-Sub) package
- [ ] Identify predicate devices
- [ ] Draft clinical trial protocol (initial)
- [ ] Risk analysis (FMEA)

**Deliverables:**
- Q-Sub package (draft)
- Clinical protocol (outline)
- Risk management file (initial)

#### Month 5: Technical Foundation
**Goals:**
- [ ] Set up development environment
- [ ] Cloud infrastructure (AWS)
- [ ] CI/CD pipeline
- [ ] Hire first engineers (backend + mobile)
- [ ] Architecture design (see System Architecture doc)

**Deliverables:**
- Infrastructure as Code (Terraform)
- Development environment documentation
- Architecture diagrams

#### Month 6: Q-Sub Submission
**Goals:**
- [ ] Submit Pre-Submission to FDA
- [ ] Finalize clinical trial design
- [ ] Series A fundraising ($10-15M)
- [ ] Complete hiring (engineering team)

**Deliverables:**
- Q-Sub submitted to FDA
- Series A funding closed
- Engineering team of 8-10

**Key Milestone: FDA Q-Sub Meeting (Month 6)**

---

## 3. Phase 1: MVP Development (Months 7-12)

### 3.1 Objectives
- Build Minimum Viable Product
- Achieve CGM + pump integration
- Develop basic closed-loop algorithm
- Complete pre-clinical testing

### 3.2 Sprint-by-Sprint Plan (2-week sprints)

**Month 7-8: Backend Foundation**

**Sprint 1 (Month 7, Week 1-2):**
- Database schema design
- User authentication service
- API gateway setup
- CI/CD pipeline

**Sprint 2 (Month 7, Week 3-4):**
- Glucose data ingestion API
- Time-series database (TimescaleDB)
- Data service implementation
- Unit tests (80% coverage target)

**Sprint 3 (Month 8, Week 1-2):**
- Insulin delivery API
- Device management service
- WebSocket real-time updates
- Integration tests

**Sprint 4 (Month 8, Week 3-4):**
- Alert service
- Notification system (push, SMS)
- Analytics service (basic)
- Load testing

**Month 9-10: Mobile App Development**

**Sprint 5 (Month 9, Week 1-2):**
- iOS: Project setup, authentication
- Android: Project setup, authentication
- Shared: UI/UX design finalized

**Sprint 6 (Month 9, Week 3-4):**
- iOS: Dashboard, glucose graph
- Android: Dashboard, glucose graph
- Bluetooth LE framework

**Sprint 7 (Month 10, Week 1-2):**
- iOS: CGM integration (Dexcom SDK)
- Android: CGM integration
- Real-time glucose display

**Sprint 8 (Month 10, Week 3-4):**
- iOS: Pump integration (Omnipod SDK)
- Android: Pump integration
- Manual insulin delivery UI

**Month 11: Algorithm Development**

**Sprint 9 (Month 11, Week 1-2):**
- ML model training (glucose prediction)
- Feature engineering pipeline
- Model evaluation

**Sprint 10 (Month 11, Week 3-4):**
- MPC controller implementation
- Safety constraints
- Algorithm service integration

**Month 12: Testing & Integration**

**Sprint 11 (Month 12, Week 1-2):**
- End-to-end testing
- Usability testing (internal)
- Bug fixes

**Sprint 12 (Month 12, Week 3-4):**
- Performance testing
- Security testing (initial)
- Documentation

**Deliverables (Month 12):**
- ✅ Working MVP (closed-loop system)
- ✅ iOS + Android apps
- ✅ Backend services deployed
- ✅ Pre-clinical testing complete

**Key Milestone: MVP Complete (Month 12)**

---

## 4. Phase 2: Clinical Validation (Months 13-30)

### 4.1 Objectives
- Obtain IDE approval
- Conduct feasibility study
- Conduct pivotal clinical trial
- Achieve ISO 13485 certification

### 4.2 Detailed Timeline

#### Months 13-15: Quality System & IDE

**Month 13:**
- [ ] Implement ISO 13485 quality system
- [ ] Design History File (DHF) creation
- [ ] Design controls documentation
- [ ] Software verification & validation

**Month 14:**
- [ ] Complete pre-clinical testing
  - Bench testing
  - Electrical safety (IEC 60601-1)
  - EMC testing
  - Cybersecurity assessment
- [ ] Risk analysis (ISO 14971) finalized
- [ ] Clinical protocol finalized

**Month 15:**
- [ ] IDE application submitted to FDA
- [ ] IRB applications submitted (10-15 sites)
- [ ] ISO 13485 certification audit
- [ ] Investigator training materials

**Deliverables:**
- IDE submitted
- ISO 13485 certified
- IRB approvals

**Key Milestone: ISO 13485 Certification (Month 15)**

#### Months 16-18: Feasibility Study

**Month 16:**
- [ ] IDE approval received (30 days)
- [ ] First patient enrolled (Site 1)
- [ ] Enroll 10 patients (target)

**Month 17:**
- [ ] Continue enrollment (target: 50 total)
- [ ] Ongoing data collection
- [ ] Safety monitoring (weekly)

**Month 18:**
- [ ] Complete enrollment (50 participants)
- [ ] 3-month follow-up complete for first cohort
- [ ] Data analysis
- [ ] Preliminary results

**Feasibility Study Results:**
- TIR improvement vs baseline: >10% (target)
- Zero severe adverse events
- User satisfaction: >4.0/5
- Device usability validated

**Key Milestone: Feasibility Study Complete (Month 18)**

#### Months 19-30: Pivotal Clinical Trial

**Month 19-20: Trial Preparation**
- [ ] Finalize pivotal protocol (based on feasibility learnings)
- [ ] Manufacture study devices (200+ units)
- [ ] Site initiation visits
- [ ] Update software based on feasibility feedback

**Month 21-24: Enrollment Phase**
- [ ] Enroll 240 participants (40 per site, 6 sites)
- [ ] Month 21: First 60 patients
- [ ] Month 22: Next 60 patients (total 120)
- [ ] Month 23: Next 60 patients (total 180)
- [ ] Month 24: Final 60 patients (total 240)

**Month 25-30: Follow-Up Phase**
- [ ] 6-month follow-up for all participants
- [ ] Monthly data collection
- [ ] Safety monitoring (DSMB quarterly reviews)
- [ ] Data quality checks

**Month 30: Trial Completion**
- [ ] Last patient last visit (LPLV)
- [ ] Database lock
- [ ] Statistical analysis
- [ ] Clinical study report (CSR) writing

**Deliverables:**
- Complete dataset (240 participants, 6 months)
- CSR (Clinical Study Report)
- Primary endpoint met (TIR improvement >5%)
- Safety profile acceptable

**Key Milestone: Pivotal Trial Complete (Month 30)**

---

## 5. Phase 3: Regulatory Approval (Months 31-48)

### 5.1 Objectives
- Submit PMA to FDA
- Respond to FDA questions
- Obtain FDA approval
- Prepare for commercialization

### 5.2 Timeline

#### Months 31-36: PMA Preparation

**Month 31-32: Data Analysis**
- [ ] Statistical analysis complete
- [ ] Subgroup analyses
- [ ] Safety analysis
- [ ] Clinical study report finalized

**Month 33-34: PMA Writing**
- [ ] Compile non-clinical data
- [ ] Compile clinical data
- [ ] Manufacturing documentation
- [ ] Labeling and IFU
- [ ] Risk-benefit analysis

**Month 35-36: PMA Submission**
- [ ] Internal review
- [ ] Regulatory consultant review
- [ ] Submit to FDA
- [ ] Pay user fees ($400K+)

**Key Milestone: PMA Submission (Month 36)**

#### Months 37-48: FDA Review

**Month 37-38: Acceptance Review (Day 0-45)**
- FDA reviews for completeness
- May issue "Refuse to Accept" if incomplete
- Address any deficiencies

**Month 39-42: In-Depth Review (Day 45-180)**
- FDA assigns review team
- Interactive review begins
- Respond to FDA questions (usually multiple rounds)
- Typical questions:
  - Statistical methods
  - Safety event adjudication
  - Software documentation
  - Risk analysis

**Month 43-45: Advisory Panel (if required)**
- FDA may convene advisory panel for novel devices
- Prepare presentation
- Panel meeting (1-2 days)
- Panel recommendation to FDA

**Month 46-48: Final Decision**
- FDA issues decision
- Approval (PMA)
- Approvable (requires minor changes)
- Not approvable (requires major changes)

**Key Milestone: FDA Approval (Month 48)**

**Parallel Activities (Months 31-48):**
- [ ] CE mark application (EU)
- [ ] Health Canada application
- [ ] Manufacturing scale-up
- [ ] Commercial team hiring

---

## 6. Phase 4: Launch Preparation (Months 49-52)

### 6.1 Objectives
- Manufacture devices
- Build commercial infrastructure
- Train sales and support teams
- Execute go-to-market strategy

### 6.2 Launch Preparation Activities

#### Month 49: Post-Approval Activities
- [ ] Finalize labeling (FDA-approved)
- [ ] Quality system for commercial production
- [ ] Post-market surveillance plan
- [ ] Scale manufacturing (contract manufacturers)

#### Month 50: Commercial Infrastructure
- [ ] Hire sales team (10-15 reps)
- [ ] Hire customer support team (24/7 coverage)
- [ ] Establish distribution channels
- [ ] Payer negotiations (insurance reimbursement)
- [ ] Pricing strategy finalized

#### Month 51: Training & Marketing
- [ ] Sales training program
- [ ] Support team training
- [ ] Healthcare provider education
- [ ] Patient education materials
- [ ] Marketing campaign launch
- [ ] Website and e-commerce

#### Month 52: Soft Launch
- [ ] Limited release (1-2 regions)
- [ ] Closely monitor first 100 users
- [ ] Customer feedback collection
- [ ] Address any issues

**Key Milestone: Commercial Launch (Month 52)**

### 6.3 Go-to-Market Strategy

**Target Markets (Year 1):**
1. **Early Adopters:** Tech-savvy T1D patients already using CGM + pump
2. **Endocrinology Clinics:** Partner with 50-100 clinics
3. **Geographic Focus:** US only (Year 1)

**Distribution Channels:**
1. **Direct-to-Consumer:** Online ordering
2. **Healthcare Providers:** Prescription-based
3. **Diabetes Clinics:** Clinic partnerships
4. **DME Suppliers:** Durable medical equipment companies

**Pricing (Estimated):**
- **Subscription:** $100/month (all-inclusive)
- **Insurance:** Covered as DME (Durable Medical Equipment)
- **Target:** 90% insurance coverage

**Marketing Channels:**
1. Digital marketing (Google, Facebook)
2. Diabetes conferences (ADA, EASD)
3. Patient advocacy groups
4. Endocrinologist outreach
5. Social media (patient testimonials)

---

## 7. Post-Launch: Continuous Improvement

### 7.1 Objectives
- Collect real-world evidence
- Improve algorithms
- Expand device compatibility
- International expansion

### 7.2 Post-Launch Roadmap

**Year 1 Post-Launch:**
- [ ] Enroll 5,000 users
- [ ] Collect real-world data
- [ ] Monthly algorithm updates
- [ ] Expand to additional CGM/pump models
- [ ] Launch smartwatch app

**Year 2:**
- [ ] 20,000 users
- [ ] International launch (EU, Canada)
- [ ] Advanced features (meal photo carb estimation, voice logging)
- [ ] Pediatric indication (FDA submission)

**Year 3:**
- [ ] 50,000+ users
- [ ] Multi-hormone system (insulin + glucagon)
- [ ] AI-powered personalized coaching
- [ ] Partnership with healthcare systems

---

## 8. Risk Management & Contingencies

### 8.1 Timeline Risks

| Risk | Probability | Impact | Mitigation |
|------|------------|--------|------------|
| FDA Q-Sub meeting delayed | Medium | High | Submit early, follow up proactively |
| Slow clinical trial enrollment | High | High | More sites, patient stipends, marketing |
| FDA requests additional studies | Medium | Very High | Engage early, be conservative in protocol |
| Manufacturing delays | Medium | Medium | Dual source suppliers, safety stock |
| Cybersecurity breach | Low | Very High | Defense in depth, security audits |

### 8.2 Budget Contingency

**Total Budget (to Launch): $30-50M**

- Phase 0 (Foundation): $3-5M
- Phase 1 (MVP): $5-7M
- Phase 2 (Clinical): $10-15M
- Phase 3 (Regulatory): $5-8M
- Phase 4 (Launch): $7-10M
- Contingency (20%): $6-10M

**Funding Strategy:**
- Seed: $2-5M (Month 1)
- Series A: $10-15M (Month 6)
- Series B: $20-30M (Month 24)
- Series C (if needed): $30-50M (Month 36)

---

## 9. Success Metrics

### 9.1 Development Metrics

**By Month 12 (MVP):**
- ✓ Closed-loop system functional
- ✓ >80% code coverage
- ✓ <500ms API latency (p95)
- ✓ Zero critical bugs

**By Month 18 (Feasibility):**
- ✓ 50 participants enrolled and completed
- ✓ TIR improvement >10%
- ✓ Zero severe adverse events
- ✓ User satisfaction >4.0/5

**By Month 30 (Pivotal):**
- ✓ 240 participants enrolled and completed
- ✓ Primary endpoint met (TIR >5% improvement)
- ✓ Safety profile acceptable
- ✓ Regulatory submission-ready

**By Month 48 (Approval):**
- ✓ FDA approval obtained
- ✓ Manufacturing capacity: 10,000 units/year
- ✓ Commercial team hired and trained

### 9.2 Post-Launch Metrics (Year 1)

**User Metrics:**
- 5,000 active users
- 70%+ TIR average
- 90% retention rate
- 4.5+ app rating

**Business Metrics:**
- $6M ARR (Annual Recurring Revenue)
- <$1,000 customer acquisition cost (CAC)
- Lifetime value (LTV) > $5,000
- Gross margin >60%

**Technical Metrics:**
- 99.9% uptime
- <5% alert false positive rate
- <20 mg/dL prediction RMSE

---

## 10. Team Scaling Plan

### 10.1 Headcount by Department

| Department | Month 6 | Month 12 | Month 24 | Month 48 |
|------------|---------|----------|----------|----------|
| Executive | 4 | 5 | 6 | 8 |
| Engineering | 8 | 12 | 15 | 20 |
| Data Science | 2 | 3 | 5 | 8 |
| Product | 2 | 3 | 4 | 6 |
| Clinical/Regulatory | 4 | 6 | 8 | 10 |
| Quality | 1 | 2 | 4 | 6 |
| Operations | 2 | 3 | 5 | 8 |
| Sales/Marketing | 0 | 0 | 3 | 15 |
| Support | 0 | 1 | 3 | 10 |
| **Total** | **23** | **35** | **53** | **91** |

---

## Appendix A: Detailed Gantt Chart

```
                  Year 1      Year 2      Year 3      Year 4      Year 5
                  ||||||||    ||||||||    ||||||||    ||||||||    ||||||||
Foundation        ████████
MVP Development           ████████
ISO 13485                     ████████
Feasibility Study                 ████████
Pivotal Trial                         ████████████████
PMA Preparation                                   ████████
PMA Review                                            ████████████████
Launch Prep                                                       ████████
Post-Market                                                           ████████
```

---

## Appendix B: Decision Points & Go/No-Go Gates

**Gate 1 (Month 6): Proceed to MVP?**
- Criteria: FDA Q-Sub positive, funding secured, team hired
- Decision: Go / No-Go

**Gate 2 (Month 12): Proceed to Clinical?**
- Criteria: MVP functional, pre-clinical testing passed
- Decision: Go / No-Go

**Gate 3 (Month 18): Proceed to Pivotal?**
- Criteria: Feasibility study successful, safety profile good
- Decision: Go / No-Go / Pivot

**Gate 4 (Month 36): Submit PMA?**
- Criteria: Pivotal trial successful, endpoints met
- Decision: Go / No-Go / Conduct additional study

**Gate 5 (Month 52): Launch Commercially?**
- Criteria: FDA approval, manufacturing ready, sales team ready
- Decision: Go / Delay

---

**Document Approval:**
- CEO: _________________
- CTO: _________________
- VP Regulatory: _________________
- VP Clinical: _________________

**Change Log:**
| Version | Date | Author | Changes |
|---------|------|--------|---------|
| 1.0 | 2025-11-23 | Initial | First draft |
